Carib A. Oquendo

Array ( [id] => 12247348 [patent_doc_number] => 09920115 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Single domain serum albumin binding protein' [patent_app_type] => utility [patent_app_number] => 15/704513 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15488 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715697 [patent_doc_number] => 20190248912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ABCG2 MONOCLONAL ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/333532 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479133 [patent_doc_number] => 20180291109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => ANTIBODIES, BINDING FRAGMENTS, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/683685 [patent_app_country] => US [patent_app_date] => 2017-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15683685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12217581 [patent_doc_number] => 20180055940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'ANTIBODY AND PROTEIN FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/679053 [patent_app_country] => US [patent_app_date] => 2017-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 8304 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15679053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925314 [patent_doc_number] => 11046776 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Multivalent and multiepitopic antibodies having agonistic activity and methods of use [patent_app_type] => utility [patent_app_number] => 15/669861 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 110443 [patent_no_of_claims] => 96 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15669861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14439065 [patent_doc_number] => 20190177405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => ANTI-ANNEXIN A2 MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/321020 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16321020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15512785 [patent_doc_number] => 10562968 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/655086 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 37381 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15655086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12346920 [patent_doc_number] => 09951143 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof [patent_app_type] => utility [patent_app_number] => 15/655105 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 15 [patent_no_of_words] => 11462 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15655105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158863 [patent_doc_number] => 20180030128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'TREATMENT OF CANCER WITH ANTI-LAP MONOCLONAL ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/649373 [patent_app_country] => US [patent_app_date] => 2017-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 52041 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15649373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704391 [patent_doc_number] => 10954311 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Trispecific binding proteins and methods of use [patent_app_type] => utility [patent_app_number] => 15/630259 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14105 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15630259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092572 [patent_doc_number] => 20170349665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'ANTI-CD52 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/625361 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 21806 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15625361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11993984 [patent_doc_number] => 20170298139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/624441 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 75789 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393406 [patent_doc_number] => 11242408 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis [patent_app_type] => utility [patent_app_number] => 16/309860 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12479 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702505 [patent_doc_number] => 20180126001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => ANTIBODY-VACCINE ENGINEERED CONSTRUCTS (AVEC) [patent_app_type] => utility [patent_app_number] => 15/620679 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15620679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689631 [patent_doc_number] => 20170355770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis [patent_app_type] => utility [patent_app_number] => 15/620771 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15620771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13645755 [patent_doc_number] => 09849176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-26 [patent_title] => RS7 antibodies [patent_app_type] => utility [patent_app_number] => 15/613928 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 23057 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15613928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15512793 [patent_doc_number] => 10562972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Antibodies targeting B-cell maturation antigen and methods of use [patent_app_type] => utility [patent_app_number] => 15/613986 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 10 [patent_no_of_words] => 41571 [patent_no_of_claims] => 67 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 899 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15613986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12685459 [patent_doc_number] => 20180120319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS [patent_app_type] => utility [patent_app_number] => 15/614513 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15614513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977637 [patent_doc_number] => 20170281791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/606447 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 41094 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15606447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717223 [patent_doc_number] => 20170369566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/603124 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 618 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15603124 [rel_patent_id] =>[rel_patent_doc_number] =>)